Renee Lengagne
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Conditional IL4I1 Inactivation Triggers Tumor-Associated Macrophage Reprogramming and CD8+ T-cell Reactivation to Control Melanoma Progression.
Journal: Cancer immunology research
Published: November 15, 2024
Upregulation of IL4-induced gene 1 enzyme by B2 cells during melanoma progression impairs their antitumor properties.
Journal: European journal of immunology
Published: June 19, 2023
Inflammation drives nitric oxide synthase 2 expression by γδ T cells and affects the balance between melanoma and vitiligo associated melanoma.
Journal: Oncoimmunology
Published: January 17, 2018
IL4-induced gene 1 promotes tumor growth by shaping the immune microenvironment in melanoma.
Journal: Oncoimmunology
Published: November 22, 2016
IL-4-Induced Gene 1: A Negative Immune Checkpoint Controlling B Cell Differentiation and Activation.
IL-4-Induced Gene 1: A Negative Immune Checkpoint Controlling B Cell Differentiation and Activation.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: September 15, 2016
Nitric oxide synthase 2 is involved in the pro-tumorigenic potential of γδ17 T cells in melanoma.
Journal: Oncoimmunology
Published: June 03, 2016
Nitric Oxide Synthase 2 Improves Proliferation and Glycolysis of Peripheral γδ T Cells.
Journal: PloS one
Published: May 12, 2016
Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 24, 2013
HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: February 01, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026